版本:
中国

FDA grants priority review to Roche's Lucentis for mCNV

ZURICH Oct 11 The U.S. Food and Drug Administration has granted priority review for Roche drug Lucentis for treating myopic choroidal neovascularization (mCNV), the Swiss drugmaker said on Tuesday.

The ailment is a complication of severe near-sightedness that can lead to blindness, it added in a statement. (Reporting by Michael Shields, editing by John Revill)

更多 瑞士市场报道

热门文章

编辑推荐

文章推荐